Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Circulating Levels of Interleukin-35 in Patients with Multiple Sclerosis: Evaluation of the Influences of FOXP3 Gene Polymorphism and Treatment Program.
Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP).
EOP, a Newly Synthesized Ethyl Pyruvate Derivative, Attenuates the Production of Inflammatory Mediators via p38, ERK and NF-κB Pathways in Lipopolysaccharide-Activated BV-2 Microglial Cells.
[Assessment of the effectiveness and safety of Sativex ® in compassionate use].
Development of a Human Dihydroorotate Dehydrogenase (hDHODH) Pharma-Similarity Index Approach with Scaffold-Hopping Strategy for the Design of Novel Potential Inhibitors.
Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring.
Ophthalmic manifestations of systemic diseases-part 2: metabolic, infections, granulomatoses, demyelination, and skeletal dysplasias.
Seminal vesicle fluid ameliorates experimental autoimmune encephalomyelitis by increasing FoxP3(+) regulatory T-cell numbers.
Reply: Microcystic macular degeneration from optic neuropathy: not inflammatory, not trans-synaptic degeneration.
Effects of whole-body vibration training on physical function in patients with Multiple Sclerosis.
Assessing dalfampridine efficacy in the physician's office.
Towards an endophenotype in multiple sclerosis.
Autoantibodies in neuroimmunological diseases; relevance of fine specificity.
The changing landscape of voltage-gated calcium channels in neurovascular disorders and in neurodegenerative diseases.
New Poteintial Serum Biomarkers in Multiple Sclerosis Identified by Proteomic Strategies.
Cannabidiol in Humans-The Quest for Therapeutic Targets.
[New challenges in multiple sclerosis treatment].
Gender differences in multiple sclerosis: induction of estrogen signaling in male and progesterone signaling in female lesions.
Polyreactive monoclonal autoantibodies in multiple sclerosis: functional selection from phage display library and characterization by deep sequencing analysis.
[STUDY ON RELATIONSHIP BETWEEN DIFFUSION TENSOR IMAGING AND VISUAL EVOKED POTENTIAL IN VISUAL PATHWAY OF NEUROMYELITIS OPTICA].
Role of myelin sheath energy metabolism in neurodegenerative diseases.
Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.
Quality of life and cognitive functions in early onset multiple sclerosis.
Cord blood mononuclear cells prevent neuronal apoptosis in response to perinatal asphyxia in the newborn lamb.
NLRP3 inflammasome and its inhibitors: a review.
Pages
« first
‹ previous
…
564
565
566
567
568
569
570
571
572
…
next ›
last »